Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
This real-world analysis investigated patients with follicular lymphoma in Italy receivingthree or more treatment lines (3L), focusing on therapeutic pathways with their rebounds onhealthcare resource consumptions and costs. Data were retrieved from administrative databases fromhealthcare entities covering about 13.3 million residents. Adults diagnosed with follicular lymphomawere identified between January 2015 and June 2020, and among… Leggi tutto »Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
Characteristics and drug utilization of patients with hereditary angioedema in Italy, a real world-analysis
This real-world analysis investigated the characteristics and treatment patterns of patientswith hereditary angioedema (HAE) in Italy using the administrative data of health units across Italy.Patients were identified via exemption code or HAE-specific treatments (thus, all known forms, typeI, II and, III, were included). The index date was that of first prescription of HAE treatments withinthe… Leggi tutto »Characteristics and drug utilization of patients with hereditary angioedema in Italy, a real world-analysis
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
Background: This real-world analysis evaluated drug utilization focusing on wastage and healthcare costsfor treatment of patients with advanced breast cancer (aBC) hormone receptor-positive (HR+)/humanepidermal growth factor receptor-2 negative (HER2-) in Italy.Methods: A retrospective analysis was conducted on administrative data covering about 13.3 millionhealth-assisted individuals. Across January/2017–June/2021, all patients with HR+/HER2-aBC wereidentified by ≥ 1 prescription… Leggi tutto »Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
Epidemiology, Patients’ Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
This real-world analysis aims to estimate the epidemiology and economic burden related to early-stage non-small-cell lung carcinoma (eNSCLC) in the clinical practice Italian setting. An observational analysis was performed using administrative databases linked to pathological anatomy data, covering around 2.5 mln health-assisted individuals. From 2015 to mid-2021, eNSCLC patients staged II–IIIA treated with chemotherapy after… Leggi tutto »Epidemiology, Patients’ Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
Introduction: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients with CML in terms of survival and quality of life. This real-world analysis evaluated the economic burden for managing… Leggi tutto »The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
Purpose: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy.Patients and Methods: An observational study on administrative databases from a sample of Italian entities was carried-out.Between 01/2010–12/2017, patients with ≥1 MS diagnosis code (ICD-9-CM:340 and/or exemption… Leggi tutto »The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis